How GLP-1 Affects Gastric Emptying: Mechanisms, Satiety Pathways, and Clinical Implications

What delayed gastric emptying means

Gastric emptying is the rate at which the stomach passes its contents into the small intestine. It sets how fast a meal's carbohydrate reaches the gut and how steep the glucose rise after eating is. In type 2 diabetes, slowed gastric emptying is integral to reducing after-meal blood glucose responses [4], and reviews of GLP-1 biology list inhibition of gastric emptying among the hormone's best-known actions [7][8].

The labels spell it out. The Wegovy label states that WEGOVY delays gastric emptying and that this may impact the absorption of oral medicines taken at the same time [1]. The Foundayo label states that FOUNDAYO delays gastric emptying and carries the same warning about oral medicines [3]. The Ozempic label describes 'a minor delay in gastric emptying' [5], and the tirzepatide labels state that tirzepatide delays gastric emptying [6].

Satiety involves more than the stomach

Label text places GLP-1 receptors in several brain areas involved in appetite regulation [1]. A 2026 review in the New England Journal of Medicine lists direct effects on hypothalamic nuclei that enhance satiety alongside reduced gastric emptying among the mechanisms of these drugs [2]. A 2025 review in the American Journal of Medicine separates central pathways acting on appetite-regulating brain regions from peripheral ones that include insulin release, glucagon suppression, delayed gastric emptying and gut hormones [9]. A 2022 review compares the vagal afferent route with GLP-1 receptor populations in the brain for the reduction of food intake [10].

Gastroparesis: what the labels say and do not say

The Wegovy and Foundayo labels both state that the drug is not recommended in patients with severe gastroparesis, under a warning about severe gastrointestinal adverse reactions [1][3]. The same labels do not say that GLP-1 receptor agonists cause gastroparesis [1][3].

The labeled gastrointestinal effects are common and track dose. With Wegovy 2.4 mg versus placebo in trials of up to 68 weeks: nausea 44% vs 16%, diarrhea 30% vs 16%, vomiting 24% vs 6%, constipation 24% vs 11% [1]. With Foundayo 17.2 mg versus placebo in trials of up to 72 weeks: nausea 35% vs 10%, vomiting 24% vs 4%, diarrhea 25% vs 11%, constipation 24% vs 9% [3]. With Zepbound 15 mg: nausea 28% vs 8%, vomiting 13% vs 2%, diarrhea 23% vs 8%, constipation 11% vs 5% [6]. Adverse reactions led to discontinuation in 6.8% versus 3.2% of Wegovy and placebo patients [1], 8% versus 3% on Foundayo overall and 10% at the 17.2 mg dose [3], and 6.7% versus 3.4% on Zepbound 15 mg [6]. Rates from separate trials are not directly comparable [1][3].

Other oral medicines

Because the stomach empties more slowly, an oral medicine taken at the same time may be absorbed differently. The labels ask for closer attention rather than a single rule. The Wegovy label advises increased clinical or laboratory monitoring for oral drugs with a narrow therapeutic index or that require clinical monitoring, and notes that the 1 mg weekly semaglutide injection did not affect the absorption of oral medicines in pharmacology trials, while a study of the semaglutide tablet found levothyroxine exposure increased 33% [1].

The labels differ on hormonal contraception and on specific drugs:

Before surgery or deep sedation

The Wegovy label warns that pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists, and says patients should report any planned surgery or procedure [1]. The Foundayo label carries the same warning and instruction [3].

A 2024 review in the Lancet Gastroenterology and Hepatology explains the concern: marked slowing of gastric emptying may leave food in the stomach longer, raising aspiration risk at surgery or upper endoscopy, and it notes that building pre-procedural guidelines is hampered by a poor evidence base, particularly for how long-acting GLP-1 receptor agonists affect emptying [4].

Do the stomach side effects ease?

The Foundayo label gives the clearest time course: nausea, vomiting and diarrhea were more frequent during dosage escalation and decreased over time [3]. That label also reports gastrointestinal adverse reactions in 60% of patients on 5.5 mg, 68% on 9 mg and 69% on 17.2 mg, against 37% on placebo [3].

Nutrients, not just drugs

A 2026 narrative review of six studies covering 480,825 adults reported that GLP-1 receptor agonist users may be prone to micronutrient shortfalls through appetite suppression, delayed gastric emptying and altered absorption. Vitamin D deficiency was found in 7.5% at 6 months and 13.6% at 12 months, ferritin levels were 26% to 30% lower than in people taking SGLT2 inhibitors, and more than 60% of users consumed less calcium and iron than estimated requirements [12]. The authors note the findings come mainly from observational data, so causality is not established [12].